Review of mechanisms of action of fluvoxamine and other SSRIs that could be beneficial for COVID-19 treatment, including lower platelet aggregation, decreased mast cell degranulation, interference with endolysosomal viral trafficking, regulation of inositol-requiring enzyme 1α-driven inflammation, and increased melatonin levels.
Sukhatme et al., 4/20/2021, peer-reviewed, 4 authors.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary;
multiple approaches are required to protect all people from all existing and
future variants. We do not provide medical advice. Before taking any
medication, consult a qualified physician who can provide personalized advice
and details of risks and benefits based on your medical history and situation.
Treatment protocols for physicians are available from the FLCCC.